Horizon Pharma in Duexis patent settlement

22 August 2013

(NYSE: PRX) to resolve pending patent litigation involving Duexis (ibuprofen and famotidine) tablets, indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis.

Under the accord, Horizon has granted Par the non-exclusive right to market a generic ibuprofen and famotidine product in the USA under Par's Abbreviated New Drug Application, beginning January 1, 2023, or earlier under certain circumstances. Currently, Horizon has listed six Orange Book patents covering Duexis. The settlement agreement includes a stipulation by the parties requesting dismissal without prejudice of the law suit filed by Horizon in the US District Court for the District of Delaware relating to the ANDA filed by Par with the US Food and Drug Administration for a generic version of Duexis (The Pharma Letter March 29, 2012).

Settlement details confidential and subject to FTC and DoJ review

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK